Idorsia’s JERAYGO (aprocitentan) approved in Switzerland for the treatment of resistant hypertension

Allschwil, Switzerland – September 19, 2025
Idorsia Ltd (SIX: IDIA) announces that Swissmedic has granted marketing authorization for JERAYGO^™ (aprocitentan) for the treatment of resistant hypertension in adult patients in combination with at least three antihypertensive medicinal products.¹ The recommended dose is 12.5 mg orally once daily. The dose can be increased to 25 mg once daily for patients tolerating the 12.5 mg dose and in need of tighter blood pressure (BP) control.¹